Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael C Perry

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Oncology (Williston Park, N.Y.)|October 23, 2003
Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary reportRamaswamy Govindan, William Read, Joan Faust, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2010
Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599Julie R Brahmer, Suzanne E Dahlberg, Robert J Gray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2002
Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431Everett E Vokes, James E Herndon, Jeffrey Crawford, et al.
Cancer|May 31, 2008
Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancerSuresh Ramalingam, Michael C Perry, Renato V La Rocca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observationChandra P Belani, John Barstis, Michael C Perry, et al.
Leukemia & Lymphoma|October 30, 2009
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901John C Byrd, Bercedis L Peterson, Kanti R Rai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trialSuresh Ramalingam, John Barstis, Michael C Perry, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590Heather A Wakelee, Patricia Stephenson, Steven M Keller, et al.
The Journal of Thoracic and Cardiovascular Surgery|June 30, 2004
Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 diseaseSteven M Keller, Mark G Vangel, Henry Wagner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 2, 2008
Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancerFilippo de Marinis, Jose Rodrigues Pereira, Frank Fossella, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Oncology (Williston Park, N.Y.)|October 23, 2003
Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary reportRamaswamy Govindan, William Read, Joan Faust, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2010
Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599Julie R Brahmer, Suzanne E Dahlberg, Robert J Gray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2002
Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431Everett E Vokes, James E Herndon, Jeffrey Crawford, et al.
Cancer|May 31, 2008
Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancerSuresh Ramalingam, Michael C Perry, Renato V La Rocca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observationChandra P Belani, John Barstis, Michael C Perry, et al.
Leukemia & Lymphoma|October 30, 2009
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901John C Byrd, Bercedis L Peterson, Kanti R Rai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trialSuresh Ramalingam, John Barstis, Michael C Perry, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590Heather A Wakelee, Patricia Stephenson, Steven M Keller, et al.
The Journal of Thoracic and Cardiovascular Surgery|June 30, 2004
Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 diseaseSteven M Keller, Mark G Vangel, Henry Wagner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 2, 2008
Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancerFilippo de Marinis, Jose Rodrigues Pereira, Frank Fossella, et al.
Pageof 5